Remdesivir, Hydroxychloroquine and COVID-19.

The article focuses on the hydroxychloroquine (HCQ ), a generic drug developed originally as a treatment for malaria. Topics include HCQ used in the treatment of COVID-19 disease; the use of HCQ for Covid in various countries has provided a quasi-experiment to assess its efficacy; and early use of H...

Descripción completa

Detalles Bibliográficos
Publicado en:Quadrant Magazine Vol. 64; no. 11; pp. 22 - 28
Autor principal: Kellow, Aynsley
Formato: Artículo
Publicado: Quadrant Magazine Co Inc. Nov2020
Materias:
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=hlh&AN=146760587&site=ehost-live
header:
  @attributes:
    shortDbName: hlh
    uiTerm: 146760587
    longDbName: Humanities International Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    jinfo:
      jid:
        00335002
        QUA
      jtl: Quadrant Magazine
      issn: 00335002
      maglogo: N
    pubinfo:
      dt: Nov2020
      vid: 64
      iid: 11
      pid: 1578
      pub: Quadrant Magazine Co Inc.
    artinfo:
      ui: 146760587
      ppf: 22
      ppct: 6
      formats:
        fmt:
          @attributes:
            type: P
            size: 2.7MB
      tig:
        atl: Remdesivir, Hydroxychloroquine and COVID-19.
      aug:
        au: Kellow, Aynsley
        affil: Professor Emeritus of Government at the University of Tasmania.
      su:
        Hydroxychloroquine
        Generic drugs
        Malaria
        COVID-19
        Death
      sug:
        subj:
          Hydroxychloroquine
          Generic drugs
          Malaria
          COVID-19
          Death
      ab: The article focuses on the hydroxychloroquine (HCQ ), a generic drug developed originally as a treatment for malaria. Topics include HCQ used in the treatment of COVID-19 disease; the use of HCQ for Covid in various countries has provided a quasi-experiment to assess its efficacy; and early use of HCQ in COVID-19 disease show a 78 per cent reduction in deaths per million compared with those with limited early use.
      pubtype: Periodical
      doctype: Article
      src: R
    language: English
    refInfo:
    copyright:
      @attributes:
        flag: Y
      custom: Copyright of Quadrant Magazine is the property of Quadrant Magazine Co Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use.
      item: Quadrant Magazine
      holder: Quadrant Magazine Co Inc.
      dt:
        @attributes:
          year: 2020
    holdings:
      @attributes:
        islocal: N